BBOT – bridgebio oncology therapeutics, inc. (US:NASDAQ)
Stock Stats
News
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is now covered by analysts at Weiss Ratings. They set a "sell (d+)" rating on the stock.
BridgeBio Oncology Therapeutics (NASDAQ:BBOT) was upgraded by analysts at Raymond James Financial, Inc. to a "moderate buy" rating.
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Ka Pipeline Programs
BBOT to Present at the 44th Annual J.P. Morgan Healthcare Conference
Form 4 BridgeBio Oncology Thera For: Jan 01 Filed by: Wallace Eli M.
Form 4 BridgeBio Oncology Thera For: Dec 10 Filed by: Wallace Eli M.
Form S-1 Helix Acquisition Corp.
Form 4 BridgeBio Oncology Thera For: Oct 10 Filed by: BridgeBio Pharma, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.